Endocare Rejects Unsolicited Proposal From HealthTronics

    IRVINE, Calif., Aug. 13 /EMWNews/ -- Endocare, Inc.

(Nasdaq: ENDO) announced today that its Board of Directors has unanimously

rejected the unsolicited proposal from HealthTronics, Inc. (Nasdaq: HTRN)

to purchase all of the outstanding shares of Endocare for $2.28 per share.

After careful evaluation, the Board determined that the proposal is

inadequate and not in the best interests of Endocare's stockholders.

    About Endocare



    Endocare, Inc. -- http://www.endocare.com -- is an innovative medical

device company focused on the development of minimally invasive

technologies for tissue and tumor ablation. Endocare has initially

concentrated on developing technologies for the treatment of prostate

cancer and believes that its proprietary technologies have broad

applications across a number of markets, including the ablation of tumors

in the kidney, lung and liver and palliative intervention (treatment of

pain associated with metastases).






     Investor Contact:     Media Contact:         For Additional

     Matt Clawson          Len Hall                Information:

     Allen & Caron, Inc.   Allen & Caron, Inc.    Craig T. Davenport, CEO

     (949) 474-4300        (949) 474-4300         Michael R. Rodriguez, CFO

     [email protected]   [email protected]     Endocare, Inc.

     http://www.allencaron.com    http://www.allencaron.com     (949) 450-5400

                                                  http://www.endocare.com